EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime

Michael R Jacobs iD, Ayman M Abdelhamed, Caryn E Good, Andrew R Mack iD, Christopher R Bethel, Steven Marshall, Andrea M Hujer, Kristine M Hujer, Robin Patel iD, David van Duin iD, Vance G Fowler, Daniel D Rhoads iD und 5 weitere

Antimicrobial Agents and Chemotherapy · 04.09.2024 · 68 (9)

DOI: 10.1128/aac.00751-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.09.2024. Verfasst von Michael R Jacobs und 16 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cefepime, Pseudomonas aeruginosa, Microbial Sensitivity Tests, Klebsiella pneumoniae. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, U.S. Department of Veterans Affairs (VA), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Taniborbactam, a bicyclic boronate β-lactamase inhibitor with activity against Klebsiella pneumoniae carbapenemase (KPC), Verona integron–encoded metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM), extended-spectrum beta-lactamases (ESBLs), OXA-48, and AmpC β-lactamases, is under clinical development in combination with cefepime. Susceptibility of 200 previously characterized carbapenem-resistant K. pneumoniae and 197 multidrug-resistant (MDR) Pseudomonas aeruginosa to cefepime-taniborbactam and comparators was determined by broth microdilution. For K. pneumoniae (192 KPC; 7 OXA-48-related), MIC 90 values of β-lactam components for cefepime-taniborbactam, ceftazidime-avibactam, and meropenem-vaborbactam were 2, 2, and 1 mg/L, respectively. For cefepime-taniborbactam, 100% and 99.5% of isolates of K. pneumoniae were inhibited at ≤16 mg/L and ≤8 mg/L, respectively, while 98.0% and 95.5% of isolates were susceptible to ceftazidime-avibactam and meropenem-vaborbactam, respectively. For P. aeruginosa , MIC 90 values of β-lactam components of cefepime-taniborbactam, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam were 16, >8, >8, and >4 mg/L, respectively. Of 89 carbapenem-susceptible isolates, 100% were susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and cefepime-taniborbactam at ≤8 mg/L. Of 73 carbapenem-intermediate/resistant P. aeruginosa isolates without carbapenemases, 87.7% were susceptible to ceftolozane-tazobactam, 79.5% to ceftazidime-avibactam, and 95.9% and 83.6% to cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively. Cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively, was active against 73.3% and 46.7% of 15 VIM- and 60.0% and 35.0% of 20 KPC-producing P. aeruginosa isolates. Of all 108 carbapenem-intermediate/resistant P. aeruginosa isolates, cefepime-taniborbactam was active against 86.1% and 69.4% at ≤16 mg/L and ≤8 mg/L, respectively, compared to 59.3% for ceftolozane-tazobactam and 63.0% for ceftazidime-avibactam. Cefepime-taniborbactam had in vitro activity comparable to ceftazidime-avibactam and greater than meropenem-vaborbactam against carbapenem-resistant K. pneumoniae and carbapenem-intermediate/resistant MDR P. aeruginosa .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefepimePseudomonas aeruginosaMicrobial Sensitivity TestsKlebsiella pneumoniaeAnti-Bacterial Agentsbeta-Lactamase InhibitorsDrug Resistance, Multiple, BacterialCephalosporinsHumansbeta-LactamasesBoronic AcidsCarbapenemsBacterial ProteinsCeftazidimeBorinic AcidsDrug CombinationsAzabicyclo CompoundsCarboxylic Acids

Stichwörter der Autor:innen

Klebsiella pneumoniaePseudomonas aeruginosabeta-lactamase inhibitorbicyclic boronatecefepime taniborbactamtaniborbactam

Substanzen

CefepimeAnti-Bacterial Agentstaniborbactambeta-Lactamase InhibitorsCephalosporinsbeta-LactamasesBoronic AcidsCarbapenemsBacterial ProteinsCeftazidime

Autor:innen und Institutionen

  • Case Western Reserve University, Cleveland, Ohio, USA.
  • University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
  • Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Research Service, Cleveland, Ohio, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Michael R Jacobs, Andrew R Mack, Robin Patel, David van Duin, Daniel D Rhoads, David A Six, Greg Moeck, Tsuyoshi Uehara, Krisztina M Papp-Wallace, Robert A Bonomo

Förderung

  • NIAID NIH HHS
  • U.S. Department of Veterans Affairs (VA)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • BLRD VA

Zitieren

APA

Jacobs, M. R., Abdelhamed, A. M., Good, C. E., Mack, A. R., Bethel, C. R., Marshall, S., Hujer, A. M., Hujer, K. M., Patel, R., van Duin, D., Fowler, V. G., Rhoads, D. D., Six, D. A., Moeck, G., Uehara, T., Papp-Wallace, K. M., & Bonomo, R. A. (2024). ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime. Antimicrobial Agents and Chemotherapy, 68(9). https://doi.org/10.1128/aac.00751-24

Vancouver

Jacobs MR, Abdelhamed AM, Good CE, Mack AR, Bethel CR, Marshall S, et al. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime. Antimicrobial Agents and Chemotherapy. 2024;68(9). doi:10.1128/aac.00751-24

BibTeX
@article{Jacobs2024,
  author = {Jacobs, Michael R and Abdelhamed, Ayman M and Good, Caryn E and Mack, Andrew R and Bethel, Christopher R and Marshall, Steven and Hujer, Andrea M and Hujer, Kristine M and Patel, Robin and van Duin, David and Fowler, Vance G and Rhoads, Daniel D and Six, David A and Moeck, Greg and Uehara, Tsuyoshi and Papp-Wallace, Krisztina M and Bonomo, Robert A},
  title = {ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {9},
  doi = {10.1128/aac.00751-24}
}
Kostenlos starten →